- ESVONC
- Avenue Ceramique 222
- 6221 KX Maastricht
- The Netherlands
- Tel: +31(0)43 325 05 21
- office@esvonc.com
last updated: 13/09/2023
ESVONC attaches great importance to innovation and evidence-based medicine in the field of veterinary oncology. Therefore, we are happy to share with you with a monthly overview of ongoing canine oncology trials in Europe. We are convinced that knowledge of these trials will enhance collaboration between researchers and clinicians, thus increasing recruitment for clinical trials and treatment options for dogs.
Please find below a non-exhaustive listing of ongoing trials as gathered in the Oncowaf database. For more details about these trials, please visit https://oncowaf.be/en/ClinicalTrials.
If you have an ongoing clinical trial and would like to add it to the Oncowaf clinical trial database and this mailing, please contact contact@oncowaf.com.
This list is an intiative of dr. Laetitia Cicchelero (DVM, PhD, Cross-health coordinator @ Faculty of Veterinary Medicine, Ghent University). Laetitia is initiator and inspirer of ONCOWAF. ESVONC wishes to thank Laetitia for her efforts to create this useful overview.
This list is updated on a monthly basis.
(green: new trial, orange: trial enters its last month of recruitment).
Country | Requested tumour types for clinical trial | Type of trial | |
Belgium | Head & Neck tumours | Fluorescence-guided surgery | Hilde de Rooster hilde.derooster@ugent.be Nayra Valle nayra.valle@ugent.be |
Osteosarcoma, chondrosarcoma, benign osteolytic lesions | Percutaneous cementoplasty | Stella Minnoye Stella.minnoye@anicura.be |
|
France | Multicentric lymphoma | Use of diffusion MRI to assess the extent of multicentric lymphoma | onco.chuvac@vetagro-sup.fr |
All tumours managed by a metronomic chemotherapy protocol | Pharmacokinetic study of metronomic chemotherapy agents residues | onco.chuvac@vetagro-sup.fr | |
Anal sac adenocarcinoma Thyroid tumour Nasal tumour Head and neck tumour Transitional cell carcinoma - bladder Chemodectoma Pheochromocytoma Gastro-intestinal stromal tumour |
Undisclosed | contact@fregis.com | |
Hepatocellular carcinoma | Ultrasound technology to ablate tumour nodules during surgery (dissectron) | contact@fregis.com | |
Solid tumours | Immunotherapy | Oncovet Clinical Research, Laurène Van Overbeke lvanoverbeke@oncovet-clinical-research.com |
|
Glioma | Oral treatment | Oncovet Clinical Research, Laurène Van Overbeke lvanoverbeke@oncovet-clinical-research.com |
|
Compassionate protocol for dogs with metastatic, recurrent or resistant cancer | Intravenous monoclonal antibody treatment | Oncovet Clinical Research, Asma Hamitouche ahamitouche@oncovet-clinical-research.com, Karolina Ziomek kziomek@oncovet-clinical-research.com |
|
Poland | Compassionate protocol for dogs with metastatic, recurrent or resistant cancer | Intravenous monoclonal antibody treatment | Oncovet Clinical Research, Asma Hamitouche ahamitouche@oncovet-clinical-research.com, Karolina Ziomek kziomek@oncovet-clinical-research.com |
Portugal | Compassionate protocol for dogs with metastatic, recurrent or resistant cancer | Intravenous monoclonal antibody treatment | Oncovet Clinical Research, Asma Hamitouche ahamitouche@oncovet-clinical-research.com Karolina Ziomek kziomek@oncovet-clinical-research.com |
Spain | Mammary carcinoma | Use of metronomic chlorambucil, firocoxib and/or their combination as adjuvant therapy | Pachi Clemente veterinario@lamerced.net |
Oral melanoma | Therapeutic trial for dogs with metastatic disease not amenable to surgical treatment | Enrique Rodriguez enrique.rodriguez@ulpgc.es |
|
Sweden | Mammary carcinoma | Use of metronomic chlorambucil, firocoxib and/or their combination as adjuvant therapy | Annika Tranaeus-Rowe Specialistdjursjukhusetstromsholm @evidensia.se |
Switzerland | Sinonasal tumours | Heterogenous dose treatment radiotherapy | Carla Bley onkologie@vetclinics.uzh.ch |
High-grade glioma | Chemoradiation for high-grade glioma | Carla Bley onkologie@vetclinics.uzh.ch |
|
Cutaneous mast cell tumours | Lymphography and lymphoscintigraphy for sentinel node mapping and resection | Mirja Nolff mnolff@vetclinics.uzh.ch |
|
Oral tumours | Fluorescence-guided surgery | Mirja Nolff mnolff@vetclinics.uzh.ch |
|
Peripheral nerve sheath tumour of the brachial or lumbar plexus | Fluorescence-guided surgery | Mirja Nolff mnolff@vetclinics.uzh.ch |
|
Soft tissue sarcoma | Fluorescence-guided surgery | Mirja Nolff mnolff@vetclinics.uzh.ch |
|
The Netherlands | Metastatic or recurrent insulinoma | Prospective evaluation of palliative and adjuvant toceranib phosphate therapy | Floryne Buishand fbuishand@rvc.ac.uk |
Brain tumours | Minimally invasive radiotherapy (injection of radioactive holmium spheres) | Bas Van Nimwegen s.a.vanNimwegen@uu.nl |
|
Lymphoma | Efficacy of PEG-L-asparaginase treatment | https://bit.ly/3RdrKm2 | |
Pheochromocytoma | Study and sample collection of pheochromoctomas to allow development of therapy for inoperable tumours | https://bit.ly/3Zg2iyf | |
United Kingdom | All tumour types | Aspartame for the prevention of chemotherapy-induced diarrhoea | HFSAreception@ed.ac.uk |
Metastatic or recurrent insulinoma | Prospective evaluation of palliative and adjuvant toceranib phosphate therapy | Floryne Buishand fbuishand@rvc.ac.uk |
|
Mammary carcinoma | Use of metronomic chlorambucil, firocoxib and/or their combination as adjuvant therapy | Gerry Polton enquiries@ndsr.co.uk |
ESVONC does not endorse any of the clinical studies listed above, and expressly disclaims any responsibility or liability for any of the content related to these studies. The use of the ESVONC listing for the purpose of recruitment can, however, be acknowledged in the material and methods of these studies.